Luveltamab tazevibulin demonstrated a 32% overall response rate in platinum-resistant ovarian cancer patients with FRα expression ≥25%, showing similar efficacy in both low-medium and high expression subgroups.
Mirvetuximab soravtansine receives European Commission approval for treating FRα-positive, platinum-resistant ovarian cancer after 1-3 prior systemic treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.